Intra-Cellular Therapies to Present at the JMP Securities Life Sciences Conference 2015

NEW YORK, June 17, 2015 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, will present at the JMP Securities Life Sciences Conference 2015 in New York, NY. The presentation is scheduled for Tuesday, June 23, 2015 at 3:30 PM EDT.

The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical trials for the treatment of schizophrenia. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.

CONTACT: Intra-Cellular Therapies, Inc.

         Juan Sanchez, M.D.
         Vice President
         Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc.
         Phone:  212-923-3344

         Burns McClellan, Inc.
         Lisa Burns/Carol Werther (Investors)
         [email protected]
         [email protected]
         Justin Jackson (Media)
         [email protected]
         212-213-0006

Source: Intra-Cellular Therapies, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Intra-Cellular Therapies (ITCI) PT Raised to $107 at Canaccord Genuity
• BayCare's St. Joseph's Hospital Opens Season's Café with Amazon's Just Walk Out Technology
• SEMIFIVE Collaborates with MetisX in Developing CXL-based Memory Accelerator Chip